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52-3042/Copyright ª 2015, Chongqi
BY-NC-ND license (http://creativeMultiple sclerosis (MS), a leading cause of non-traumatic
disability in young adults, is a chronic inflammatory demye-
linating disease of the central nervous system (CNS) associ-
ated with aberrant autoimmune responses. It has long been
thought that therapeutic development should be centered on
immunomodulatory agents. However, none of the agents
tested could prevent chronic progressive disease and
disability. On the other hand, direct repair of injured myelin
might represent an alternative strategy for treating MS. This
may be achieved by either promoting the inherent repair
mechanism of neurons or by recruiting cells derived from
oligodendrocyte progenitor cells (OPCs), which are unfortu-
nately silent in MS. The latter approach was recently
demonstrated by Najm et al at Case Western Reserve Uni-
versity and Northwestern University.1 They demonstrated
that miconazole and clobetasol, screened from a library of
bioactive smallmolecules onmouse pluripotent epiblast stem
cell-derived OPCs,2e4 promoted precocious myelination,
significantly increased the number of new oligodendrocytes
andenhanced remyelination. Strikingly, both smallmolecules
reversed the disease severity in mouse models of MS.
The subsequent genome-wide RNA sequencing and phos-
phoproteomic analyses on mouse OPCs showed that the ac-
tivity of clobetasol is mediated by the glucocorticoid
receptor signaling axis, whereas miconazole functionsity of Chongqing Medical
015.06.001
ng Medical University. Production
commons.org/licenses/by-nc-nd/through the mitogen-activated protein (MAP) kinase
pathway,with potential cell-type specificity. To interpret the
potential impact of these treatments on immune cell survival
and function, subsequent immune response assays were
performed, which showed that only clobetasol alters the
naı¨ve T-cell differentiation and secretion of cytokines. These
findings indicate that clobetasol plays a role in both immu-
nomodulation and the promotion of myelination, whereas
miconazole acts as a direct remyelinating agent, with no
effect on the immune system. Most importantly, both drugs
enhanced the generation of human oligodendrocytes from
human OPCs in vitro, with miconazole exhibiting the most
reproducible and potent effects. Although miconazole and
clobetasol are currently only approved for topical adminis-
tration in humans, meaning that significant optimization of
the dosing, delivery and potentially the chemical constitu-
tion will be required to enhance the on-target pharmacology
in OPCs, this study provides new hope for the currently
untreatable chronic progressive phase of MS.
It remains unknown how the remyelinating and immune
system effects interact, and the precise mechanisms un-
derlying the resultant recovery after the administration of
these two drugs remain unclear. However, the study by Najm
et al suggests that OPCs can be selectively modified and
differentiated into oligodendrocytes by two different drugs
identified using a high-throughput screeningmethod, both of
which resulted in amelioration of the MS phenotype in vivo.
Compared with genetically engineered stem cells, which
may exhibit alterations of their structure and function that
might interfere with the microenvironment and glia-neuron
interactions, a major advantage of using drug-modified cells
is that the treatment can be stopped at any time depending
on the clinical outcome of the MS and the side effects. In
addition, themanipulation of isolated target cells provides a
new method for dealing not only with MS, but also with a
variety of other diseases, such as cancer and neurodegen-
erative diseases. For instance, the drug-based high-
throughput screening strategy used in this study could beand hosting by Elsevier B.V. This is an open access article under the
4.0/).
Commentary 223useful to identify small molecules targeting cancer stem
cells, which would ultimately lead to the optimized treat-
ment of patients with cancer. Therefore, we think that the
drug-based modulation of target cells represents a break-
through in research related to physiology and disease.
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